-
1
-
-
0030714605
-
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
-
Anderson DM, Maraskovsky E, Billingsley WL et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390(6656), 175-179 (1997).
-
(1997)
Nature
, vol.390
, Issue.6656
, pp. 175-179
-
-
Anderson, D.M.1
Maraskovsky, E.2
Billingsley, W.L.3
-
2
-
-
14444272043
-
TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells
-
Wong BR, Rho J, Arron J et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272(40), 25190-25194 (1997).
-
(1997)
J. Biol. Chem.
, vol.272
, Issue.40
, pp. 25190-25194
-
-
Wong, B.R.1
Rho, J.2
Arron, J.3
-
3
-
-
84880920106
-
RANKL-RANK interaction in immune regulatory systems
-
Akiyama T, Shinzawa M, Akiyama N. RANKL-RANK interaction in immune regulatory systems. World J. Orthop. 3(9), 142-150 (2012).
-
(2012)
World J. Orthop.
, vol.3
, Issue.9
, pp. 142-150
-
-
Akiyama, T.1
Shinzawa, M.2
Akiyama, N.3
-
4
-
-
0031005576
-
Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
-
Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89(2), 309-319 (1997).
-
(1997)
Cell
, vol.89
, Issue.2
, pp. 309-319
-
-
Simonet, W.S.1
Lacey, D.L.2
Dunstan, C.R.3
-
5
-
-
0009660825
-
Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
-
Yasuda H, Shima N, Nakagawa N et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139(3), 1329-1337 (1998).
-
(1998)
Endocrinology
, vol.139
, Issue.3
, pp. 1329-1337
-
-
Yasuda, H.1
Shima, N.2
Nakagawa, N.3
-
6
-
-
0033532191
-
Evidence for a role of a tumor necrosis factor-a (TNF-a)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival
-
Lum L, Wong BR, Josien R et al. Evidence for a role of a tumor necrosis factor-a (TNF-a)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J. Biol. Chem. 274(19), 13613-13618 (1999).
-
(1999)
J. Biol. Chem.
, vol.274
, Issue.19
, pp. 13613-13618
-
-
Lum, L.1
Wong, B.R.2
Josien, R.3
-
7
-
-
34548647431
-
RANKL RANK osteoprotegerin: Key partners of osteoimmunology and vascular diseases
-
Baud'huin M, Lamoureux F, Duplomb L, Redini F, Heymann D. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell. Mol. Life Sci. 64(18), 2334-2350 (2007).
-
(2007)
Cell. Mol. Life Sci.
, vol.64
, Issue.18
, pp. 2334-2350
-
-
Baud'Huin, M.1
Lamoureux, F.2
Duplomb, L.3
Redini, F.4
Heymann, D.5
-
8
-
-
84860364397
-
Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab
-
Lacey DL, Boyle WJ, Simonet WS et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov. 11(5), 401-419 (2012).
-
(2012)
Nat. Rev. Drug Discov.
, vol.11
, Issue.5
, pp. 401-419
-
-
Lacey, D.L.1
Boyle, W.J.2
Simonet, W.S.3
-
9
-
-
75349090418
-
Regulation of osteoprotegerin pro-or anti-tumoral activity by bone tumor microenvironment
-
Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Redini F. Regulation of osteoprotegerin pro-or anti-tumoral activity by bone tumor microenvironment. Biochim. Biophys. Acta 1805(1), 17-24 (2010).
-
(2010)
Biochim. Biophys. Acta
, vol.1805
, Issue.1
, pp. 17-24
-
-
Lamoureux, F.1
Moriceau, G.2
Picarda, G.3
Rousseau, J.4
Trichet, V.5
Redini, F.6
-
10
-
-
0033599563
-
A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/ RANKL, regulates osteoclast differentiation and function
-
Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun. 256(3), 449-455 (1999).
-
(1999)
Biochem. Biophys. Res. Commun.
, vol.256
, Issue.3
, pp. 449-455
-
-
Takahashi, N.1
Udagawa, N.2
Suda, T.3
-
11
-
-
0033168518
-
Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function
-
Jimi E, Akiyama S, Tsurukai T et al. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J. Immunol. 163(1), 434-442 (1999).
-
(1999)
J. Immunol.
, vol.163
, Issue.1
, pp. 434-442
-
-
Jimi, E.1
Akiyama, S.2
Tsurukai, T.3
-
12
-
-
0033611467
-
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
-
Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397(6717), 315-323 (1999).
-
(1999)
Nature
, vol.397
, Issue.6717
, pp. 315-323
-
-
Kong, Y.Y.1
Yoshida, H.2
Sarosi, I.3
-
13
-
-
0033568341
-
RANK is essential for osteoclast and lymph node development
-
Dougall WC, Glaccum M, Charrier K et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 13(18), 2412-2424 (1999).
-
(1999)
Genes Dev.
, vol.13
, Issue.18
, pp. 2412-2424
-
-
Dougall, W.C.1
Glaccum, M.2
Charrier, K.3
-
14
-
-
80053938104
-
Evidence for osteocyte regulation of bone homeostasis through RANKL expression
-
Nakashima T, Hayashi M, Fukunaga T et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17(10), 1231-1234 (2011).
-
(2011)
Nat. Med.
, vol.17
, Issue.10
, pp. 1231-1234
-
-
Nakashima, T.1
Hayashi, M.2
Fukunaga, T.3
-
15
-
-
80053978532
-
Matrix-embedded cells control osteoclast formation
-
Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat. Med. 17(10), 1235-1241 (2011).
-
(2011)
Nat. Med.
, vol.17
, Issue.10
, pp. 1235-1241
-
-
Xiong, J.1
Onal, M.2
Jilka, R.L.3
Weinstein, R.S.4
Manolagas, S.C.5
O'Brien, C.A.6
-
16
-
-
84857311721
-
Osteocyte RANKL: New insights into the control of bone remodeling
-
Xiong J, O'Brien CA. Osteocyte RANKL: new insights into the control of bone remodeling. J. Bone Miner. Res. 27(3), 499-505 (2012).
-
(2012)
J. Bone Miner. Res.
, vol.27
, Issue.3
, pp. 499-505
-
-
Xiong, J.1
O'Brien, C.A.2
-
17
-
-
84867544854
-
Immunolocalization of sclerostin synthesized by osteocytes in relation to bone remodeling in the interradicular septa of ovariectomized rats
-
Guo Y, Li M, Zhusheng L et al. Immunolocalization of sclerostin synthesized by osteocytes in relation to bone remodeling in the interradicular septa of ovariectomized rats. J. Electron. Microsc. (Tokyo) 61(5), 309-320 (2012).
-
(2012)
J. Electron. Microsc. (Tokyo)
, vol.61
, Issue.5
, pp. 309-320
-
-
Guo, Y.1
Li, M.2
Zhusheng, L.3
-
18
-
-
84865446399
-
Receptor activator of nuclear factor kB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss
-
Onal M, Xiong J, Chen X et al. Receptor activator of nuclear factor kB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J. Biol. Chem. 287(35), 29851-29860 (2012).
-
(2012)
J. Biol. Chem.
, vol.287
, Issue.35
, pp. 29851-29860
-
-
Onal, M.1
Xiong, J.2
Chen, X.3
-
19
-
-
0033398996
-
Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kB (RANK) receptors
-
Arai F, Miyamoto T, Ohneda O et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kB (RANK) receptors. J. Exp. Med. 190 (12), 1741-1754 (1999).
-
(1999)
J. Exp. Med.
, vol.190
, Issue.12
, pp. 1741-1754
-
-
Arai, F.1
Miyamoto, T.2
Ohneda, O.3
-
20
-
-
0035043292
-
Tumor necrosis factor-a cooperates with receptor activator of nuclear factor kB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture
-
Komine M, Kukita A, Kukita T, Ogata Y, Hotokebuchi T, Kohashi O. Tumor necrosis factor-a cooperates with receptor activator of nuclear factor kB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. Bone 28(5), 474-483 (2001).
-
(2001)
Bone
, vol.28
, Issue.5
, pp. 474-483
-
-
Komine, M.1
Kukita, A.2
Kukita, T.3
Ogata, Y.4
Hotokebuchi, T.5
Kohashi, O.6
-
21
-
-
84858007236
-
Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis
-
Maeda K, Kobayashi Y, Udagawa N et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat. Med. 18(3), 405-412 (2012).
-
(2012)
Nat. Med.
, vol.18
, Issue.3
, pp. 405-412
-
-
Maeda, K.1
Kobayashi, Y.2
Udagawa, N.3
-
22
-
-
33947583822
-
Osteoimmunology: Shared mechanisms and crosstalk between the immune and bone systems
-
Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7(4), 292-304 (2007).
-
(2007)
Nat. Rev. Immunol.
, vol.7
, Issue.4
, pp. 292-304
-
-
Takayanagi, H.1
-
23
-
-
6544270833
-
Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-defcient mice
-
Naito A, Azuma S, Tanaka S et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-defcient mice. Genes Cells 4(6), 353-362 (1999).
-
(1999)
Genes Cells
, vol.4
, Issue.6
, pp. 353-362
-
-
Naito, A.1
Azuma, S.2
Tanaka, S.3
-
24
-
-
34347356549
-
Eos MITF, and PU.1 recruit corepressors to osteoclast-specifc genes in committed myeloid progenitors
-
Hu R, Sharma SM, Bronisz A, Srinivasan R, Sankar U, Ostrowski MC. Eos, MITF, and PU.1 recruit corepressors to osteoclast-specifc genes in committed myeloid progenitors. Mol. Cell. Biol. 27(11), 4018-4027 (2007).
-
(2007)
Mol. Cell. Biol.
, vol.27
, Issue.11
, pp. 4018-4027
-
-
Hu, R.1
Sharma, S.M.2
Bronisz, A.3
Srinivasan, R.4
Sankar, U.5
Ostrowski, M.C.6
-
25
-
-
70349100754
-
2+-NFATc1 signaling is an essential axis of osteoclast differentiation
-
2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol. Rev. 231(1), 241-256 (2009).
-
(2009)
Immunol. Rev.
, vol.231
, Issue.1
, pp. 241-256
-
-
Negishi-Koga, T.1
Takayanagi, H.2
-
26
-
-
70450207475
-
A unique domain in RANK is required for Gab2 and PLCg2 binding to establish osteoclastogenic signals
-
Taguchi Y, Gohda J, Koga T, Takayanagi H, Inoue J. A unique domain in RANK is required for Gab2 and PLCg2 binding to establish osteoclastogenic signals. Genes Cells 14(11), 1331-1345 (2009).
-
(2009)
Genes Cells
, vol.14
, Issue.11
, pp. 1331-1345
-
-
Taguchi, Y.1
Gohda, J.2
Koga, T.3
Takayanagi, H.4
Inoue, J.5
-
27
-
-
33750597150
-
PLCg2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2
-
Mao D, Epple H, Uthgenannt B, Novack DV, Faccio R. PLCg2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J. Clin. Invest. 116(11), 2869-2879 (2006).
-
(2006)
J. Clin. Invest.
, vol.116
, Issue.11
, pp. 2869-2879
-
-
Mao, D.1
Epple, H.2
Uthgenannt, B.3
Novack, D.V.4
Faccio, R.5
-
29
-
-
5444229284
-
RANKL-induced DC-STAMP is essential for osteoclastogenesis
-
Kukita T, Wada N, Kukita A et al. RANKL-induced DC-STAMP is essential for osteoclastogenesis. J. Exp. Med. 200(7), 941-946 (2004).
-
(2004)
J. Exp. Med.
, vol.200
, Issue.7
, pp. 941-946
-
-
Kukita, T.1
Wada, N.2
Kukita, A.3
-
30
-
-
23744459835
-
DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells
-
Yagi M, Miyamoto T, Sawatani Y et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J. Exp. Med. 202(3), 345-351 (2005).
-
(2005)
J. Exp. Med.
, vol.202
, Issue.3
, pp. 345-351
-
-
Yagi, M.1
Miyamoto, T.2
Sawatani, Y.3
-
31
-
-
12744269233
-
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression
-
Maeda T, Hobbs RM, Merghoub T et al. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 433(7023), 278-285 (2005).
-
(2005)
Nature
, vol.433
, Issue.7023
, pp. 278-285
-
-
Maeda, T.1
Hobbs, R.M.2
Merghoub, T.3
-
32
-
-
34248580502
-
Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF
-
Maeda T, Merghoub T, Hobbs RM et al. Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science 316(5826), 860-866 (2007).
-
(2007)
Science
, vol.316
, Issue.5826
, pp. 860-866
-
-
Maeda, T.1
Merghoub, T.2
Hobbs, R.M.3
-
33
-
-
70350061670
-
LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis
-
Maeda T, Ito K, Merghoub T et al. LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. Dev. Cell 17(4), 527-540 (2009).
-
(2009)
Dev. Cell
, vol.17
, Issue.4
, pp. 527-540
-
-
Maeda, T.1
Ito, K.2
Merghoub, T.3
-
34
-
-
79960004649
-
The LRF transcription factor regulates mature B cell development and the germinal center response in mice
-
Sakurai N, Maeda M, Lee SU et al. The LRF transcription factor regulates mature B cell development and the germinal center response in mice. J. Clin. Invest. 121(7), 2583-2598 (2011).
-
(2011)
J. Clin. Invest.
, vol.121
, Issue.7
, pp. 2583-2598
-
-
Sakurai, N.1
Maeda, M.2
Lee, S.U.3
-
35
-
-
0033568579
-
Osteoclast-derived zinc fnger (OCZF) protein with POZ domain, a possible transcriptional repressor, is involved in osteoclastogenesis
-
Kukita A, Kukita T. Ouchida M et al. Osteoclast-derived zinc fnger (OCZF) protein with POZ domain, a possible transcriptional repressor, is involved in osteoclastogenesis. Blood 94(6) 1987-1997 (1999).
-
(1999)
Blood
, vol.94
, Issue.6
, pp. 1987-1997
-
-
Kukita, A.1
Kukita, T.2
Ouchida, M.3
-
36
-
-
80052331060
-
The transcription factor FBI-1/OCZF/LRF is expressed in osteoclasts and regulates RANKL-induced osteoclast formation in vitro and in vivo
-
Kukita A, Kukita T, Nagata K et al. The transcription factor FBI-1/OCZF/LRF is expressed in osteoclasts and regulates RANKL-induced osteoclast formation in vitro and in vivo. Arthritis Rheum. 63(9), 2744-2754 (2011).
-
(2011)
Arthritis Rheum.
, vol.63
, Issue.9
, pp. 2744-2754
-
-
Kukita, A.1
Kukita, T.2
Nagata, K.3
-
37
-
-
84857130450
-
Stage-specifc functions of leukemia/lymphoma-related factor (LRF) in the transcriptional control of osteoclast development
-
Tsuji-Takechi K, Negishi-Koga T, Sumiya E et al. Stage-specifc functions of leukemia/lymphoma-related factor (LRF) in the transcriptional control of osteoclast development. Proc. Natl Acad. Sci. USA 109(7), 2561-2566 (2012).
-
(2012)
Proc. Natl Acad. Sci. USA
, vol.109
, Issue.7
, pp. 2561-2566
-
-
Tsuji-Takechi, K.1
Negishi-Koga, T.2
Sumiya, E.3
-
38
-
-
83755225707
-
The osteoclast and its unique cytoskeleton
-
Teitelbaum SL. The osteoclast and its unique cytoskeleton. Ann. NY Acad. Sci. 1240, 14-17 (2011).
-
(2011)
Ann. NY Acad. Sci.
, vol.1240
, pp. 14-17
-
-
Teitelbaum, S.L.1
-
39
-
-
84863991650
-
C-Src links a RANK/avb3 integrin complex to the osteoclast cytoskeleton
-
Izawa T, Zou W, Chappel JC, Ashley J W, Feng X, Teitelbaum SL. c-Src links a RANK/avb3 integrin complex to the osteoclast cytoskeleton. Mol. Cell. Biol. 32(14), 2943-2953 (2012).
-
(2012)
Mol. Cell. Biol.
, vol.32
, Issue.14
, pp. 2943-2953
-
-
Izawa, T.1
Zou, W.2
Chappel, J.C.3
Ashley, J.W.4
Feng, X.5
Teitelbaum, S.L.6
-
40
-
-
79958852901
-
The regulation of osteoclast function and bone resorption by small GTPases
-
Itzstein C, Coxon FP, Rogers MJ. The regulation of osteoclast function and bone resorption by small GTPases. Small GTPases 2 (3), 117-130 (2011).
-
(2011)
Small GTPases
, vol.2
, Issue.3
, pp. 117-130
-
-
Itzstein, C.1
Coxon, F.P.2
Rogers, M.J.3
-
41
-
-
21644438825
-
Ranking the role of RANK ligand in apoptosis
-
Bharti AC, Aggarwal BB. Ranking the role of RANK ligand in apoptosis. Apoptosis 9(6), 677-690 (2004).
-
(2004)
Apoptosis
, vol.9
, Issue.6
, pp. 677-690
-
-
Bharti, A.C.1
Aggarwal, B.B.2
-
42
-
-
13444291284
-
Regulation of apoptosis in osteoclasts and osteoblastic cells
-
Xing L, Boyce BF. Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem. Biophys. Res. Commun. 328(3), 709-720 (2005).
-
(2005)
Biochem. Biophys. Res. Commun.
, vol.328
, Issue.3
, pp. 709-720
-
-
Xing, L.1
Boyce, B.F.2
-
43
-
-
0033393957
-
TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src
-
Wong BR, Besser D, Kim N et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell. 4(6), 1041-1049 (1999).
-
(1999)
Mol. Cell.
, vol.4
, Issue.6
, pp. 1041-1049
-
-
Wong, B.R.1
Besser, D.2
Kim, N.3
-
44
-
-
0033888977
-
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo
-
Lacey DL, Tan HL, Lu J et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am. J. Pathol. 157(2), 435-448 (2000).
-
(2000)
Am. J. Pathol.
, vol.157
, Issue.2
, pp. 435-448
-
-
Lacey, D.L.1
Tan, H.L.2
Lu, J.3
-
45
-
-
20444481078
-
RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts
-
Wu X, Pan G, McKenna MA, Zayzafoon M, Xiong WC, McDonald JM. RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts. J. Bone Miner. Res. 20(1), 107-116 (2005).
-
(2005)
J. Bone Miner. Res.
, vol.20
, Issue.1
, pp. 107-116
-
-
Wu, X.1
Pan, G.2
McKenna, M.A.3
Zayzafoon, M.4
Xiong, W.C.5
McDonald, J.M.6
-
46
-
-
46049108371
-
Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway
-
Chamoux E, Houde N, L'Eriger K, Roux S. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J. Cell. Physiol. 216(2), 536-542 (2008).
-
(2008)
J. Cell. Physiol.
, vol.216
, Issue.2
, pp. 536-542
-
-
Chamoux, E.1
Houde, N.2
L'Eriger, K.3
Roux, S.4
-
47
-
-
78649470387
-
Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: Role in osteoclastogenesis and bone resorption
-
Baud'huin M, Ruiz-Velasco C, Jego G et al. Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption. Eur. J. Cell. Biol. 90 (1), 49-57 (2011).
-
(2011)
Eur. J. Cell. Biol.
, vol.90
, Issue.1
, pp. 49-57
-
-
Baud'Huin, M.1
Ruiz-Velasco, C.2
Jego, G.3
-
48
-
-
41849089744
-
Heparin inhibits osteoclastic differentiation and function
-
Ariyoshi W, Takahashi T, Kanno T et al. Heparin inhibits osteoclastic differentiation and function. J. Cell. Biochem. 103(6), 1707-1717 (2008).
-
(2008)
J. Cell. Biochem.
, vol.103
, Issue.6
, pp. 1707-1717
-
-
Ariyoshi, W.1
Takahashi, T.2
Kanno, T.3
-
49
-
-
34347220458
-
Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity
-
Irie A, Takami M, Kubo H, Sekino-Suzuki N, Kasahara K, Sanai Y. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 41(2), 165-174 (2007).
-
(2007)
Bone
, vol.41
, Issue.2
, pp. 165-174
-
-
Irie, A.1
Takami, M.2
Kubo, H.3
Sekino-Suzuki, N.4
Kasahara, K.5
Sanai, Y.6
-
50
-
-
58349111534
-
Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma
-
Lamoureux F, Picarda G, Garrigue-Antar L et al. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. Cancer Res. 69(2), 526-536 (2009).
-
(2009)
Cancer Res.
, vol.69
, Issue.2
, pp. 526-536
-
-
Lamoureux, F.1
Picarda, G.2
Garrigue-Antar, L.3
-
51
-
-
79953078905
-
Bone metastasis: Mechanisms and therapeutic opportunities
-
Suva LJ, Washam C, Nicholas RW, Griffn RJ. Bone metastasis: mechanisms and therapeutic opportunities. Nat. Rev. Endocrinol. 7(4), 208-218 (2011).
-
(2011)
Nat. Rev. Endocrinol.
, vol.7
, Issue.4
, pp. 208-218
-
-
Suva, L.J.1
Washam, C.2
Nicholas, R.W.3
Griffn, R.J.4
-
52
-
-
78649320264
-
Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: Stimulation of epithelial to mesenchymal transition (EMT)
-
Martin FT, Dwyer RM, Kelly J et al. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res. Treat. 124(2), 317-326 (2010).
-
(2010)
Breast Cancer Res. Treat.
, vol.124
, Issue.2
, pp. 317-326
-
-
Martin, F.T.1
Dwyer, R.M.2
Kelly, J.3
-
53
-
-
81255205399
-
Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis
-
Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20(5), 576-590 (2011).
-
(2011)
Cancer Cell
, vol.20
, Issue.5
, pp. 576-590
-
-
Labelle, M.1
Begum, S.2
Hynes, R.O.3
-
54
-
-
84867115486
-
Microenvironmental regulation of epithelial-mesenchymal transitions in cancer
-
Gao D, Vahdat LT, Wong S, Chang JC, Mittal V. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res. 72(19), 4883-4889 (2012).
-
(2012)
Cancer Res.
, vol.72
, Issue.19
, pp. 4883-4889
-
-
Gao, D.1
Vahdat, L.T.2
Wong, S.3
Chang, J.C.4
Mittal, V.5
-
55
-
-
57349101056
-
Osteotropic cancers: From primary tumor to bone
-
Buijs JT, van der Pluijm G. Osteotropic cancers: from primary tumor to bone. Cancer Lett. 273(2), 177-193 (2009).
-
(2009)
Cancer Lett.
, vol.273
, Issue.2
, pp. 177-193
-
-
Buijs, J.T.1
Van Der Pluijm, G.2
-
56
-
-
79952193038
-
Tu m o u r-infltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling
-
Tan W, Zhang W, Strasner A et al. Tu m o u r-infltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470(7335), 548-553 (2011).
-
(2011)
Nature
, vol.470
, Issue.7335
, pp. 548-553
-
-
Tan, W.1
Zhang, W.2
Strasner, A.3
-
57
-
-
81155123656
-
Targeting regulatory T cells in cancer
-
Byrne WL, Mills KH, Lederer JA, O'Sullivan GC. Targeting regulatory T cells in cancer. Cancer Res. 71(22), 6915-6920 (2012).
-
(2012)
Cancer Res.
, vol.71
, Issue.22
, pp. 6915-6920
-
-
Byrne, W.L.1
Mills, K.H.2
Lederer, J.A.3
O'Sullivan, G.C.4
-
58
-
-
84863569576
-
CXCL10 promotes osteolytic bone metastasis by enhancing cancer outgrowth and osteoclastogenesis
-
Lee JH, Kim HN, Kim KO et al. CXCL10 promotes osteolytic bone metastasis by enhancing cancer outgrowth and osteoclastogenesis. Cancer Res. 72(13), 3175-3186.
-
Cancer Res.
, vol.72
, Issue.13
, pp. 3175-3186
-
-
Lee, J.H.1
Kim, H.N.2
Kim, K.O.3
-
59
-
-
33750073849
-
RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4
-
Nakamura ES, Koizumi K, Kobayashi M et al. RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. Clin. Exp. Metastasis 23(1), 9-18 (2006).
-
(2006)
Clin. Exp. Metastasis
, vol.23
, Issue.1
, pp. 9-18
-
-
Nakamura, E.S.1
Koizumi, K.2
Kobayashi, M.3
-
60
-
-
33645453481
-
Regulation of cancer cell migration and bone metastasis by RANKL
-
Jones DH, Nakashima T, Sanchez OH et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440(7084), 692-696 (2006).
-
(2006)
Nature
, vol.440
, Issue.7084
, pp. 692-696
-
-
Jones, D.H.1
Nakashima, T.2
Sanchez, O.H.3
-
61
-
-
3142684493
-
Expression and function of RANK in human monocyte chemotaxis
-
Mosheimer BA, Kaneider NC, Feistritzer C, Sturn DH, Wiedermann CJ. Expression and function of RANK in human monocyte chemotaxis. Arthritis Rheum. 50(7), 2309-2316 (2004).
-
(2004)
Arthritis Rheum.
, vol.50
, Issue.7
, pp. 2309-2316
-
-
Mosheimer, B.A.1
Kaneider, N.C.2
Feistritzer, C.3
Sturn, D.H.4
Wiedermann, C.J.5
-
62
-
-
84858199187
-
Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition
-
Gao D, Joshi N, Choi H et al. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res. 72(6), 1384-1394 (2012).
-
(2012)
Cancer Res.
, vol.72
, Issue.6
, pp. 1384-1394
-
-
Gao, D.1
Joshi, N.2
Choi, H.3
-
63
-
-
78650304106
-
Advances in the biology of bone metastasis: How the skeleton affects tumor behavior
-
Sterling JA, Edwards JR, Martin TJ, Mundy GR. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 48(1), 6-15 (2011).
-
(2011)
Bone
, vol.48
, Issue.1
, pp. 6-15
-
-
Sterling, J.A.1
Edwards, J.R.2
Martin, T.J.3
Mundy, G.R.4
-
64
-
-
4644261592
-
Mechanisms of bone metastasis
-
Roodman GD. Mechanisms of bone metastasis. N. Engl. J. Med. 350(16), 1655-1664 (2004).
-
(2004)
N. Engl. J. Med.
, vol.350
, Issue.16
, pp. 1655-1664
-
-
Roodman, G.D.1
-
65
-
-
84855999380
-
Molecular pathways: Osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis
-
Dougall WC. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin. Cancer Res. 18(2), 326-335 (2011).
-
(2011)
Clin. Cancer Res.
, vol.18
, Issue.2
, pp. 326-335
-
-
Dougall, W.C.1
-
66
-
-
84865116604
-
Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases
-
Hiraga T, Myoui A, Hashimoto N et al. Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res. 72(16), 4238-4249 (2012).
-
(2012)
Cancer Res.
, vol.72
, Issue.16
, pp. 4238-4249
-
-
Hiraga, T.1
Myoui, A.2
Hashimoto, N.3
-
67
-
-
0034730327
-
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development
-
Fata JE, Kong YY, Li J et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103(1), 41-50 (2000).
-
(2000)
Cell
, vol.103
, Issue.1
, pp. 41-50
-
-
Fata, J.E.1
Kong, Y.Y.2
Li, J.3
-
68
-
-
84860332532
-
From the ranks of mammary progesterone mediators, RANKL takes the spotlight
-
Fernandez-Valdivia R, Lydon JP. From the ranks of mammary progesterone mediators, RANKL takes the spotlight. Mol. Cell. Endocrinol. 357(1-2), 91-100 (2009).
-
(2009)
Mol. Cell. Endocrinol.
, vol.357
, Issue.1-2
, pp. 91-100
-
-
Fernandez-Valdivia, R.1
Lydon, J.P.2
-
69
-
-
79955089567
-
Receptor activator of NF-kB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit
-
Duheron V, Hess E, Duval M et al. Receptor activator of NF-kB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. Proc. Natl Acad. Sci. USA 108(13), 5342-5347 (2011).
-
(2011)
Proc. Natl Acad. Sci. USA
, vol.108
, Issue.13
, pp. 5342-5347
-
-
Duheron, V.1
Hess, E.2
Duval, M.3
-
70
-
-
78049264846
-
Synthesis of artifcial lymphoid tissue with immunological function
-
Kobayashi Y, Watanabe T. Synthesis of artifcial lymphoid tissue with immunological function. Trends Immunol. 31(11), 422-428 (2010).
-
(2010)
Trends Immunol.
, vol.31
, Issue.11
, pp. 422-428
-
-
Kobayashi, Y.1
Watanabe, T.2
-
71
-
-
84874257342
-
Emerging functions of RANKL in lymphoid tissues
-
Mueller CG, Hess E. Emerging functions of RANKL in lymphoid tissues. Front. Immunol. 3, 261 (2012).
-
(2012)
Front. Immunol.
, vol.3
, Issue.261
-
-
Mueller, C.G.1
Hess, E.2
-
72
-
-
77950491661
-
RANKL is necessary and suffcient to initiate development of antigen-sampling M cells in the intestinal epithelium
-
Knoop KA, Kumar N, Butler BR et al. RANKL is necessary and suffcient to initiate development of antigen-sampling M cells in the intestinal epithelium. J. Immunol. 183(9), 5738-5747 (2009).
-
(2009)
J. Immunol.
, vol.183
, Issue.9
, pp. 5738-5747
-
-
Knoop, K.A.1
Kumar, N.2
Butler, B.R.3
-
73
-
-
84864147310
-
The Ets transcription factor Spi-B is essential for the differentiation of intestinal microfold cells
-
Kanaya T, Hase K, Takahashi D et al. The Ets transcription factor Spi-B is essential for the differentiation of intestinal microfold cells. Nat. Immunol. 13(8), 729-736 (2012).
-
(2012)
Nat. Immunol.
, vol.13
, Issue.8
, pp. 729-736
-
-
Kanaya, T.1
Hase, K.2
Takahashi, D.3
-
74
-
-
51349092893
-
The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator
-
Hikosaka Y, Nitta T, Ohigashi I et al. The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity 29(3), 438-450 (2008).
-
(2008)
Immunity
, vol.29
, Issue.3
, pp. 438-450
-
-
Hikosaka, Y.1
Nitta, T.2
Ohigashi, I.3
-
75
-
-
51349111243
-
The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance
-
Akiyama T, Shimo Y, Yanai H et al. The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 29(3), 423-437 (2008).
-
(2008)
Immunity
, vol.29
, Issue.3
, pp. 423-437
-
-
Akiyama, T.1
Shimo, Y.2
Yanai, H.3
-
76
-
-
78650671134
-
Expression pattern of receptor activator of NFkB (RANK) in a series of primary solid tumors and related bone metastases
-
Santini D, Perrone G, Roato I et al. Expression pattern of receptor activator of NFkB (RANK) in a series of primary solid tumors and related bone metastases. J. Cell. Physiol. 226(3), 780-784 (2010).
-
(2010)
J. Cell. Physiol.
, vol.226
, Issue.3
, pp. 780-784
-
-
Santini, D.1
Perrone, G.2
Roato, I.3
-
77
-
-
79955772442
-
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients
-
Santini D, Schiavon G, Vincenzi B et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One 6(4), e19234 (2011).
-
(2011)
PLoS One
, vol.6
, Issue.4
-
-
Santini, D.1
Schiavon, G.2
Vincenzi, B.3
-
78
-
-
33745821237
-
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation
-
Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107(2), 289-298 (2006).
-
(2006)
Cancer
, vol.107
, Issue.2
, pp. 289-298
-
-
Chen, G.1
Sircar, K.2
Aprikian, A.3
Potti, A.4
Goltzman, D.5
Rabbani, S.A.6
-
79
-
-
67650924224
-
Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas
-
Mikami S, Katsube K, Oya M et al. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J. Pathol. 218(4), 530-539 (2009).
-
(2009)
J. Pathol.
, vol.218
, Issue.4
, pp. 530-539
-
-
Mikami, S.1
Katsube, K.2
Oya, M.3
-
80
-
-
84874883241
-
Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer
-
Peng X, Guo W, Ren T et al. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer. PLoS One 8(3), e58361 (2013).
-
(2013)
PLoS One
, vol.8
, Issue.3
-
-
Peng, X.1
Guo, W.2
Ren, T.3
-
81
-
-
33947646303
-
Human osteosarcoma cells express functional receptor activator of nuclear factor-kB
-
Mori K, Le Goff B, Berreur M et al. Human osteosarcoma cells express functional receptor activator of nuclear factor-kB. J. Pathol. 211(5), 555-562 (2007).
-
(2007)
J. Pathol.
, vol.211
, Issue.5
, pp. 555-562
-
-
Mori, K.1
Le Goff, B.2
Berreur, M.3
-
82
-
-
84861213409
-
Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells
-
Beristain AG, Narala SR, Di Grappa MA, Khokha R. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells. J. Cell. Sci. 125(Pt 4), 943-955 (2011).
-
(2011)
J. Cell. Sci.
, vol.125
, Issue.PART 4
, pp. 943-955
-
-
Beristain, A.G.1
Narala, S.R.2
Di Grappa, M.A.3
Khokha, R.4
-
83
-
-
79952764688
-
RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells
-
Kupas V, Weishaupt C, Siepmann D et al. RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. J. Invest. Dermatol. 131(4), 944-955 (2011).
-
(2011)
J. Invest. Dermatol.
, vol.131
, Issue.4
, pp. 944-955
-
-
Kupas, V.1
Weishaupt, C.2
Siepmann, D.3
-
84
-
-
0037389602
-
Expression of receptor activator of nuclear factor kB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma
-
Heider U, Langelotz C, Jakob C et al. Expression of receptor activator of nuclear factor kB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin. Cancer Res. 9(4), 1436-1440 (2003).
-
(2003)
Clin. Cancer Res.
, vol.9
, Issue.4
, pp. 1436-1440
-
-
Heider, U.1
Langelotz, C.2
Jakob, C.3
-
85
-
-
0037443533
-
RANK ligand and osteoprotegerin in myeloma bone disease
-
Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101(6), 2094-2098 (2003).
-
(2003)
Blood
, vol.101
, Issue.6
, pp. 2094-2098
-
-
Sezer, O.1
Heider, U.2
Zavrski, I.3
Kuhne, C.A.4
Hofbauer, L.C.5
-
86
-
-
0033305673
-
Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast
-
Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J. Clin. Endocrinol. Metab. 84(12), 4559-4565 (1999).
-
(1999)
J. Clin. Endocrinol. Metab.
, vol.84
, Issue.12
, pp. 4559-4565
-
-
Hofseth, L.J.1
Raafat, A.M.2
Osuch, J.R.3
Pathak, D.R.4
Slomski, C.A.5
Haslam, S.Z.6
-
87
-
-
78149284013
-
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer
-
Schramek D, Leibbrandt A, Sigl V et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468(7320), 98-102 (2010).
-
(2010)
Nature
, vol.468
, Issue.7320
, pp. 98-102
-
-
Schramek, D.1
Leibbrandt, A.2
Sigl, V.3
-
88
-
-
78149284767
-
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
-
Gonzalez-Suarez E, Jacob A P, Jones J et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468(7320), 103-107 (2010).
-
(2010)
Nature
, vol.468
, Issue.7320
, pp. 103-107
-
-
Gonzalez-Suarez, E.1
Jacob, A.P.2
Jones, J.3
-
89
-
-
33845543666
-
Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells
-
Loser K, Mehling A, Loeser S et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat. Med. 12(12), 1372-1379 (2006).
-
(2006)
Nat. Med.
, vol.12
, Issue.12
, pp. 1372-1379
-
-
Loser, K.1
Mehling, A.2
Loeser, S.3
-
90
-
-
73849123602
-
Expansion of antigen-specifc regulatory T cells with the topical vitamin D analog calcipotriol
-
Ghoreishi M, Bach P, Obst J, Komba M, Fleet JC, Dutz JP. Expansion of antigen-specifc regulatory T cells with the topical vitamin D analog calcipotriol. J. Immunol. 182(10), 6071-6078 (2009).
-
(2009)
J. Immunol.
, vol.182
, Issue.10
, pp. 6071-6078
-
-
Ghoreishi, M.1
Bach, P.2
Obst, J.3
Komba, M.4
Fleet, J.C.5
Dutz, J.P.6
-
91
-
-
0035861314
-
IKKa provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development
-
Cao Y, Bonizzi G, Seagroves TN et al. IKKa provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107(6), 763-775 (2001).
-
(2001)
Cell
, vol.107
, Issue.6
, pp. 763-775
-
-
Cao, Y.1
Bonizzi, G.2
Seagroves, T.N.3
-
92
-
-
31344455071
-
Receptor activator of NF-kB ligand regulates the proliferation of mammary epithelial cells via Id2
-
Kim NS, Kim HJ, Koo BK et al. Receptor activator of NF-kB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol. Cell. Biol. 26(3), 1002-1013 (2006).
-
(2006)
Mol. Cell. Biol.
, vol.26
, Issue.3
, pp. 1002-1013
-
-
Kim, N.S.1
Kim, H.J.2
Koo, B.K.3
-
93
-
-
83255186733
-
Survival and differentiation of mammary epithelial cells in mammary gland development require nuclear retention of Id2 due to RANK signaling
-
Kim NS, Kim HT, Kwon MC et al. Survival and differentiation of mammary epithelial cells in mammary gland development require nuclear retention of Id2 due to RANK signaling. Mol. Cell. Biol. 31(23), 4775-4788 (2011).
-
(2011)
Mol. Cell. Biol.
, vol.31
, Issue.23
, pp. 4775-4788
-
-
Kim, N.S.1
Kim, H.T.2
Kwon, M.C.3
-
94
-
-
77951214454
-
The helix-loop-helix Id-1 inhibits PSA expression in prostate cancer cells
-
Zielinski AJ, Fong S, Allison J et al. The helix-loop-helix Id-1 inhibits PSA expression in prostate cancer cells. Int. J. Cancer 126(10), 2490-2496 (2010).
-
(2010)
Int. J. Cancer
, vol.126
, Issue.10
, pp. 2490-2496
-
-
Zielinski, A.J.1
Fong, S.2
Allison, J.3
-
95
-
-
51049121618
-
RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis
-
Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol. Cancer Ther. 7(7), 2160-2169 (2008).
-
(2008)
Mol. Cancer Ther.
, vol.7
, Issue.7
, pp. 2160-2169
-
-
Miller, R.E.1
Roudier, M.2
Jones, J.3
Armstrong, A.4
Canon, J.5
Dougall, W.C.6
-
96
-
-
80755168375
-
The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells
-
Shin M, Matsuo K, Tada T et al. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells. Carcinogenesis 32(11), 1634-1640 (2011).
-
(2011)
Carcinogenesis
, vol.32
, Issue.11
, pp. 1634-1640
-
-
Shin, M.1
Matsuo, K.2
Tada, T.3
-
97
-
-
67649311599
-
Latent bone metastasis in breast cancer tied to Src-dependent survival signals
-
Zhang XH, Wang Q, Gerald W et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16(1), 67-78 (2009).
-
(2009)
Cancer Cell
, vol.16
, Issue.1
, pp. 67-78
-
-
Zhang, X.H.1
Wang, Q.2
Gerald, W.3
-
98
-
-
49149114127
-
Receptor activator of NF-kB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells
-
Odero-Marah VA, Wang R, Chu G et al. Receptor activator of NF-kB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res. 18(8), 858-870 (2008).
-
(2008)
Cell Res.
, vol.18
, Issue.8
, pp. 858-870
-
-
Odero-Marah, V.A.1
Wang, R.2
Chu, G.3
-
99
-
-
77954355093
-
Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration
-
Sabbota AL, Kim HR, Zhe X, Fridman R, Bonfl RD, Cher ML. Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res. 70(13), 5558-5566 (2010).
-
(2010)
Cancer Res.
, vol.70
, Issue.13
, pp. 5558-5566
-
-
Sabbota, A.L.1
Kim, H.R.2
Zhe, X.3
Fridman, R.4
Bonfl, R.D.5
Cher, M.L.6
-
100
-
-
84861854171
-
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis
-
Palafox M, Ferrer I, Pellegrini P et al. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res. 72(11), 2879-2888 (2012).
-
(2012)
Cancer Res.
, vol.72
, Issue.11
, pp. 2879-2888
-
-
Palafox, M.1
Ferrer, I.2
Pellegrini, P.3
-
101
-
-
34247274248
-
Nuclear cytokine-activated IKKa controls prostate cancer metastasis by repressing Maspin
-
Luo JL, Tan W, Ricono JM et al. Nuclear cytokine-activated IKKa controls prostate cancer metastasis by repressing Maspin. Nature 446(7136), 690-694 (2007).
-
(2007)
Nature
, vol.446
, Issue.7136
, pp. 690-694
-
-
Luo, J.L.1
Tan, W.2
Ricono, J.M.3
-
102
-
-
79960129686
-
Maspin, the molecular bridge between the plasminogen activator system and b1 integrin that facilitates cell adhesion
-
Endsley MP, Hu Y, Deng Y et al. Maspin, the molecular bridge between the plasminogen activator system and b1 integrin that facilitates cell adhesion. J. Biol. Chem. 286(28), 24599-24607 (2011).
-
(2011)
J. Biol. Chem.
, vol.286
, Issue.28
, pp. 24599-24607
-
-
Endsley, M.P.1
Hu, Y.2
Deng, Y.3
-
103
-
-
37449004858
-
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes
-
Armstrong A P, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68(1), 92-104 (2008).
-
(2008)
Prostate
, vol.68
, Issue.1
, pp. 92-104
-
-
Armstrong, A.P.1
Miller, R.E.2
Jones, J.C.3
Zhang, J.4
Keller, E.T.5
Dougall, W.C.6
-
104
-
-
66449121642
-
CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model
-
Ma X, Norsworthy K, Kundu N et al. CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol. Cancer Ther. 8(3), 490-498 (2009).
-
(2009)
Mol. Cancer Ther.
, vol.8
, Issue.3
, pp. 490-498
-
-
Ma, X.1
Norsworthy, K.2
Kundu, N.3
-
105
-
-
84868117017
-
Characterization and identifcation of subpopulations of mononuclear preosteoclasts induced by TNF-a in combination with TGF-b in rats
-
Matsubara R, Kukita T, Ichigi Y et al. Characterization and identifcation of subpopulations of mononuclear preosteoclasts induced by TNF-a in combination with TGF-b in rats. PLoS One 7(10), e47930 (2012).
-
(2012)
PLoS One
, vol.7
, Issue.10
-
-
Matsubara, R.1
Kukita, T.2
Ichigi, Y.3
-
106
-
-
0842325055
-
Direct stimulation of osteoclastogenesis by MIP-1a: Evidence obtained from studies using RAW264 cell clone highly responsive to RANKL
-
Watanabe T, Kukita T, Kukita A et al. Direct stimulation of osteoclastogenesis by MIP-1a: evidence obtained from studies using RAW264 cell clone highly responsive to RANKL. J. Endocrinol. 180(1), 193-201 (2004).
-
(2004)
J. Endocrinol.
, vol.180
, Issue.1
, pp. 193-201
-
-
Watanabe, T.1
Kukita, T.2
Kukita, A.3
-
107
-
-
84865171804
-
CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease
-
Dairaghi DJ, Oyajobi BO, Gupta A et al. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood 120(7), 1449-1457 (2012).
-
(2012)
Blood
, vol.120
, Issue.7
, pp. 1449-1457
-
-
Dairaghi, D.J.1
Oyajobi, B.O.2
Gupta, A.3
-
108
-
-
4344612243
-
NF-kB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression
-
Huber MA, Azoitei N, Baumann B et al. NF-kB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest. 114 (4), 569-581 (2004).
-
(2004)
J. Clin. Invest.
, vol.114
, Issue.4
, pp. 569-581
-
-
Huber, M.A.1
Azoitei, N.2
Baumann, B.3
-
109
-
-
84869153585
-
Salmonella transforms follicle-associated epithelial cells into M cells to promote intestinal invasion
-
Tahoun A, Mahajan S, Paxton E et al. Salmonella transforms follicle-associated epithelial cells into M cells to promote intestinal invasion. Cell Host Microbe 12(5), 645-656 (2012).
-
(2012)
Cell Host Microbe
, vol.12
, Issue.5
, pp. 645-656
-
-
Tahoun, A.1
Mahajan, S.2
Paxton, E.3
-
110
-
-
79551592979
-
New approaches to the treatment of osteoporosis
-
Silva BC, Bilezikian JP. New approaches to the treatment of osteoporosis. Annu. Rev. Med. 62, 307-322 (2011).
-
(2011)
Annu. Rev. Med.
, vol.62
, pp. 307-322
-
-
Silva, B.C.1
Bilezikian, J.P.2
-
111
-
-
69049083492
-
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
-
Cummings SR, San Martin J, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361(8), 756-765 (2009).
-
(2009)
N. Engl. J. Med.
, vol.361
, Issue.8
, pp. 756-765
-
-
Cummings, S.R.1
San Martin, J.2
McClung, M.R.3
-
112
-
-
3342982829
-
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women
-
Bekker PJ, Holloway DL, Rasmussen AS et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone. Miner. Res. 19(7), 1059-1066 (2004).
-
(2004)
J. Bone. Miner. Res.
, vol.19
, Issue.7
, pp. 1059-1066
-
-
Bekker, P.J.1
Holloway, D.L.2
Rasmussen, A.S.3
-
113
-
-
84872283943
-
Management of bone metastases in refractory prostate cancer-role of denosumab
-
Paller CJ, Carducci MA, Philips GK. Management of bone metastases in refractory prostate cancer-role of denosumab. Clin. Interv. Aging 7, 363-372 (2012).
-
(2012)
Clin. Interv. Aging
, vol.7
, pp. 363-372
-
-
Paller, C.J.1
Carducci, M.A.2
Philips, G.K.3
-
114
-
-
69049105440
-
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
-
Smith MR, Egerdie B, Hernandez Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361(8), 745-755 (2009).
-
(2009)
N. Engl. J. Med.
, vol.361
, Issue.8
, pp. 745-755
-
-
Smith, M.R.1
Egerdie, B.2
Hernandez Toriz, N.3
-
115
-
-
84855516339
-
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial
-
Smith MR, Saad F, Coleman R et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379(9810), 39-46 (2012).
-
(2012)
Lancet
, vol.379
, Issue.9810
, pp. 39-46
-
-
Smith, M.R.1
Saad, F.2
Coleman, R.3
-
116
-
-
54449084015
-
Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer
-
Ellis GK, Bone HG, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J. Clin. Oncol. 26(30), 4875-4882 (2008).
-
(2008)
J. Clin. Oncol.
, vol.26
, Issue.30
, pp. 4875-4882
-
-
Ellis, G.K.1
Bone, H.G.2
Chlebowski, R.3
-
117
-
-
79551568488
-
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study
-
Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28(35), 5132-5139 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.35
, pp. 5132-5139
-
-
Stopeck, A.T.1
Lipton, A.2
Body, J.J.3
-
118
-
-
79952761418
-
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
-
Henry DH, Costa L, Goldwasser F et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29(9), 1125-1132 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.9
, pp. 1125-1132
-
-
Henry, D.H.1
Costa, L.2
Goldwasser, F.3
-
119
-
-
58149198581
-
Extended effcacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy
-
Lipton A, Steger GG, Figueroa J et al. Extended effcacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin. Cancer Res. 14(20), 6690-6696 (2008).
-
(2008)
Clin. Cancer Res.
, vol.14
, Issue.20
, pp. 6690-6696
-
-
Lipton, A.1
Steger, G.G.2
Figueroa, J.3
-
120
-
-
35348897212
-
Randomized active-controlled Phase II study of denosumab effcacy and safety in patients with breast cancer-related bone metastases
-
Lipton A, Steger GG, Figueroa J et al. Randomized active-controlled Phase II study of denosumab effcacy and safety in patients with breast cancer-related bone metastases. J. Clin. Oncol. 25(28), 4431-4437 (2007).
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.28
, pp. 4431-4437
-
-
Lipton, A.1
Steger, G.G.2
Figueroa, J.3
-
121
-
-
84863069811
-
Denosumab and the current status of bone-modifying drugs in breast cancer
-
Lee BL, Higgins MJ, Goss PE. Denosumab and the current status of bone-modifying drugs in breast cancer. Acta Oncol. 51(2), 157-167 (2012).
-
(2012)
Acta Oncol.
, vol.51
, Issue.2
, pp. 157-167
-
-
Lee, B.L.1
Higgins, M.J.2
Goss, P.E.3
-
122
-
-
84856088337
-
EMT and dissemination precede pancreatic tumor formation
-
Rhim AD, Mirek ET, Aiello NM et al. EMT and dissemination precede pancreatic tumor formation. Cell 148(1-2), 349-361 (2012).
-
(2012)
Cell 148
, vol.1-2
, pp. 349-361
-
-
Rhim, A.D.1
Mirek, E.T.2
Aiello, N.M.3
-
123
-
-
77952095079
-
Osteoclasts are involved in the maintenance of dormant leukemic cells
-
Yokota A, Kimura S, Tanaka R et al. Osteoclasts are involved in the maintenance of dormant leukemic cells. Leuk. Res. 34(6), 793-799 (2010).
-
(2010)
Leuk. Res.
, vol.34
, Issue.6
, pp. 793-799
-
-
Yokota, A.1
Kimura, S.2
Tanaka, R.3
|